Table 2 Clinical and histopathological findings in patients and controls.

From: CD4+CD25+ T Cells in primary malignant hypertension related kidney injury

Index (mean ± SD)

Patients

Controls

BP (systolic/diastolic)

187.5 ± 16.3*/140 ± 7.2*

124 ± 11.5/73 ± 9.8

Proteinuria (g/day)

1.25 ± 0.31

–

Hematuria (×104 cells/mL)

364.75 ± 2.18

–

BUN (mg/dL)

28.7 ± 0.75*

12.5 ± 0.13

Serum Cr. (mg/dL)

6.83 ± 0.25*

0.58 ± 0.12

Serum uric acid (μmol/L)

467.62 ± 73.81*

246.37 ± 28.34

eGFR (mL/min/1.73 m2)

67.12 ± 10.23*

101.32 ± 7.41

Serum C3 (mg/dL)

119.5 ± 15.4

121.5 ± 13.7

Serum IL-2 (pg/ml)

104.6 ± 16.3*

24.7 ± 15.2

Supernatant IL-4 (pg/ml)

536 ± 24.03*

213.46 ± 35.67

Serum IL-6 (pg/ml)

60.21 ± 12.41*

30.43 ± 11.42

AI/CI (median)

10.4 ± 2.1/3.6 ± 0.5

–

vWF (%)

215.73 ± 12.40

–

VCAM (ng/mL)

1135.26 ± 143.87

–

AECA (positive %)

72

–

ADAMTS13-antibody (positive %)

81

–

  1. BP, Blood pressure; eGFR, estimated glomerular filtration rate; AI, activity index; CI, chronicity index; vWF, von Wille brand factor; VCAM, vascular cell adhesion molecule; AECA, anti -endothelial cell antibody.
  2. *P < 0.05 compared to controls.
Back to article page